Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NeoCARD: A Response-Adapted Phase II Study of Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients With Cardiomyopathy or Elevated Risk of Cardiotoxicity

NCT06845319 is registered in ClinicalTrials.gov with Medical University of South Carolina as lead sponsor.

NCT NCT06845319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06845319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NeoCARD: A Response-Adapted Phase II Study of Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients With Cardiomyopathy or Elevated Risk of Cardiotoxicity
Lead sponsor
Medical University of South Carolina
Phase
Phase 2
Overall status
Recruiting
Start date
October 20, 2025
Completion date
October 20, 2028
Enrollment
43 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer